Insider Buying Boosts Anavex Confidence Ahead of FDA Data Deadline
Insider buying spurs optimism as Anavex’s CFO and CEO buy options amid FDA dialogue on blarcamesine—high‑risk biotech, high‑reward potential.
3 minutes to read
Anavex Life Sciences Corp
Insider Moves Signal Anavex’s Confidence in FDA‑Backed Alzheimer’s Drug
CEO’s insider option buy signals confidence in Anavex’s Alzheimer drug blarcamesine and its market‑access strategy, hinting at future upside for investors.
4 minutes to read